23andMe yesterday announced that it has entered into an agreement for its sale to Regeneron Pharmaceuticals, a leading US-based biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Under the terms of the agreement, Regeneron will acquire all of the assets of 23andMe, including the Personal Genome Service, Total Health and Research Services business lines, for $256 million.
The agreement includes Regeneron’s commitment to comply with 23andMe’s privacy policies and applicable law, process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect, and have security controls in place designed to protect such data.
“We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data,” said Mark Jensen, Chair and member of the Special Committee of the Board of Directors of 23andMe.
The proposed transaction remains subject to approval by the US Bankruptcy Court for the Eastern District of Missouri, approval under the Hart-Scott-Rodino Act, and customary closing conditions.
A court hearing to consider approval of the transaction is currently scheduled for June 17, 2025, and the transaction is expected to close in the third quarter of 2025.
